Belite Bio(BLTE) - 2023 Q2 - Earnings Call Presentation

Clinical Trial & Results (STGD1) - Belite Bio's Tinlarebant (LBS-008) is in Phase 3 clinical trials for Stargardt Disease (STGD1)[6, 21] - Phase 2 interim data showed a 60% reduction in mean DAF lesion growth rate compared to a prospective cohort study[48] - In the Phase 2 study, 58.3% of subjects showed no development of DDAF at the 18-month timepoint[27] - In the Phase 2 study, plasma RBP4 levels were reduced by approximately 80% relative to baseline during daily dosing at 5 mg over 18 months[46] - In the Phase 2 study, the mean change in BCVA (ETDRS letters lost) within the study cohort over 18 months of treatment was -3 ± 1 letters in the Study eye and -2 ± 2 letters in the Fellow eye[31] Clinical Trial & Results (GA) - Belite Bio's Tinlarebant is in Phase 3 clinical trials for Geographic Atrophy (GA)[7, 21] - Phase 2 interim data continues to show slowing of lesion growth; 24-month data expected in Q4 2023[7] - Belite Bio believes that early intervention directed at emerging retinal pathology, which is not mediated by inflammation, would be the best approach to potentially slow disease progression in STGD1 & GA[7] Financial Status - Belite Bio's cash position is $57.4 million[65] - Total operating expenses for the three months ended June 30, 2023 were $6.871 million, including $5.516 million in R&D expenses and $1.355 million in G&A expenses[70] - Net loss for the three months ended June 30, 2023 was $(6.811) million[70]